Pennsylvania-based Aprecia Pharmaceuticals this week announced its intention to purchase a never-used facility in Blue Ash, OH, built by Forest Laboratories in 2013.
The FDA has sent a Form 483 to Lupin listing 6 observations its inspectors made during a visit to one of the company's production plants in central India last month. However, the ticking off has done little to slow the rate of approvals for the facility, which has racked up two site transfer nods and one ANDA go-ahead since receiving the Form 483.
After almost a year of speculation and secretive negotiations, officials in Iowa have revealed that drug distribution giant McKesson is behind the 340,000-square-foot warehouse being built in the state. McKesson will use the site to distribute products across 7 states when it starts operating in May 2016.
Connecticut-based flu vaccine maker Protein Sciences has cancelled its expansion plans after learning the governor got his flu shot from a foreign competitor. The Meriden, CT-based company nixed negotiations to buy two local properties after hearing of Gov. Dannel Malloy's faux pas.
Generics drugmaker InvaGen Pharmaceuticals and AlphaMed Bottles, both co-owned companies, said they will build two separate manufacturing facilities in Central Islip, located on Long Island, NY.
WuXi PharmaTech, China's largest CRO with nearly $350 million in new manufacturing facilities, is borrowing $165 million to help finance the construction and expansion of its production capabilities.
The Indian government is expected to announce new strategies to bolster its bulk drug manufacturing capacity as part of an effort to reduce the country's dependency on Chinese API imports.
South Korea's Samsung BioLogics has pledged to be a big deal in biosimilars, but so far its biologics subsidiary has produced mostly operating losses for its parent. In anticipation of turning that around, the company will undertake a significant expansion of the biologics plant in Songdo, Incheon, that it opened in 2013.
Videos touting manufacturing processes are again being used by a drugmaker to help launch a new product: GlaxoSmithKline's new over-the-counter version of allergy fighter Flonase, which appeared on retailers' shelves this week.
Three years out, French drugmaker Sanofi continues to reap benefits from having opened a U.S. biologics plant that added capacity for some of the rare disease meds developed by its Genzyme unit.